Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03712930
Registration number
NCT03712930
Ethics application status
Date submitted
11/10/2018
Date registered
19/10/2018
Date last updated
17/11/2021
Titles & IDs
Public title
Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency
Query!
Scientific title
A Phase 2, Open-Label, Single-Arm Study of BGB-290 (BGB-290) for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Homologous Recombination Deficiency (HRD)
Query!
Secondary ID [1]
0
0
2018-002587-28
Query!
Secondary ID [2]
0
0
BGB-290-202
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
0
0
Query!
Homologous Recombination Deficiency (HRD)
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Prostate
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Pamiparib
Experimental: Pamiparib - Participants will receive pamiparib for a period up to 1 year
Treatment: Drugs: Pamiparib
60 mg orally twice daily (BID)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Objective Response Rate (ORR) Determined by Independent Review Committee
Query!
Assessment method [1]
0
0
ORR is the percentage of participants with a best objective response of complete response (CR) or partial response (PR) confirmed at a subsequent timepoint = 4 weeks later by an Independent Review Committee (IRC).
Query!
Timepoint [1]
0
0
Up to 1 year and 6 months
Query!
Primary outcome [2]
0
0
Prostate-Specific Antigen (PSA) Response Rate
Query!
Assessment method [2]
0
0
PSA response rate is defined as the percentage of participants with PSA decline = 50% from baseline [confirmed by a second PSA value = 3 weeks later] for CTC-HRD-positive participants with or without measurable disease.
Query!
Timepoint [2]
0
0
Up to 1 year and 6 months
Query!
Secondary outcome [1]
0
0
Duration of Response (DOR) by IRC
Query!
Assessment method [1]
0
0
DOR is defined as the time from the date of the earliest documented CR or PR (that is subsequently confirmed) to radiographic disease progression or death due to any cause, whichever occurs first.
Query!
Timepoint [1]
0
0
Up to 1 year and 7 months
Query!
Secondary outcome [2]
0
0
Objective Response Rate by Investigator
Query!
Assessment method [2]
0
0
ORR is the percentage of participants with a best objective response of complete response (CR) or partial response (PR) confirmed at a subsequent timepoint = 4 weeks later by the investigator.
Query!
Timepoint [2]
0
0
Up to 1 year and 6 months
Query!
Secondary outcome [3]
0
0
Time to Objective Response by Investigator
Query!
Assessment method [3]
0
0
Time to objective response is defined as the time from the date of the first dose of study drug to the first documented confirmed response of CR or PR assessed by the investigator and summarized for participants who have achieved a confirmed objective response.
Query!
Timepoint [3]
0
0
Up to 1 year and 6 months
Query!
Secondary outcome [4]
0
0
Clinical Benefit Rate By Investigator
Query!
Assessment method [4]
0
0
Clinical Benefit Rate is the percentage of participants who achieved confirmed CR, PR, or SD or NON-CR/NON-PD. The minimum interval for confirmed CR and PR is 4 weeks and the measurement of SD or NON-CR/NON-PD is 7 weeks after first dose date.
Query!
Timepoint [4]
0
0
Up to 1 year and 6 months
Query!
Secondary outcome [5]
0
0
Time to PSA Response
Query!
Assessment method [5]
0
0
Time to PSA response is defined as the time from the date of the first dose of study drug to the first PSA decline = 50% that is subsequently confirmed. Assessments are summarized for participants who have achieved a confirmed PSA response.
Query!
Timepoint [5]
0
0
Up to 1 year and 6 months
Query!
Secondary outcome [6]
0
0
Duration of PSA Response
Query!
Assessment method [6]
0
0
Duration of PSA response is defined as the time from the date of the earliest documented PSA response (that is subsequently confirmed) to PSA progression or death due to any cause, whichever occurs first. PSA progression is defined as a = 25% increase in PSA with an absolute increase of = 2 µg/L above the nadir (or above the baseline for participants with no PSA decline) after12 weeks, confirmed by a second value = 3 weeks later. The nadir is defined as the lowest value at or after baseline.
Query!
Timepoint [6]
0
0
Up to 1 year and 7 months
Query!
Secondary outcome [7]
0
0
Time to PSA Progression
Query!
Assessment method [7]
0
0
Time to PSA progression is defined as the time from the date of the first dose of study drug to a = 25% increase in PSA with an absolute increase of = 2 ng/mL above the nadir (or above the baseline for participants with no PSA decline) after 12 weeks, confirmed by a second value = 3 weeks later. Death for the participants with no PSA progression is also considered as an event.
Query!
Timepoint [7]
0
0
Up to 1 year and 7 months
Query!
Secondary outcome [8]
0
0
Time to Symptomatic Skeletal Event
Query!
Assessment method [8]
0
0
Time to symptomatic skeletal event (SSE) is defined as time from the date of the first dose of study drug to the first symptomatic fracture, radiation or surgery to bone, or spinal cord compression.
Query!
Timepoint [8]
0
0
Up to 1 year and 7 months
Query!
Secondary outcome [9]
0
0
Radiographic Progression-Free Survival by IRC
Query!
Assessment method [9]
0
0
Radiographic progression-free survival is defined as the time from the date of the first dose of study drug to radiographic disease progression by IRC or death due to any cause, whichever occurs first.
Query!
Timepoint [9]
0
0
Up to 1 year and 7 months
Query!
Secondary outcome [10]
0
0
Overall Survival (OS)
Query!
Assessment method [10]
0
0
Overall survival is defined as the time from the date of the first dose of study drug to death due to any cause.
Query!
Timepoint [10]
0
0
Up to 1 year and 7 months
Query!
Secondary outcome [11]
0
0
Number of Participants With Treatment-Emergent Adverse Events Graded According to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
From the date of first Pamiparib dose until 30 days after the last dose or initiation of new anti-cancer therapy, whichever occurs first. (Up to 1 year and 7 months)
Query!
Eligibility
Key inclusion criteria
Key
- Men (= 18 years of age) with histologically or cytologically confirmed adenocarcinoma
or poorly differentiated adenocarcinoma of the prostate without neuroendocrine
differentiation with HRD deficiency by CTC-HRD assay and/or deleterious germline or
somatic mutation in BRCA1 or BRCA2; mCRPC measurable disease and/or bone disease. •
PSA progression with = 3 rising PSA levels with = 1 week between determinations and a
screening PSA = 2 µg/L (2 ng/mL).
- Must be surgically or medically castrated with serum testosterone levels of =1.73
nmol/L (50 ng/dL), must have received = 1 prior androgen receptor-targeted therapy,
and must have received = 1 taxane-based therapy.
- mCRPC with 1 or 2 of the following:
- Measurable disease per RECIST v1.1
- Bone disease
- CTC-HRD+ or BRCA1/2 mutation
- PSA progression (PCWG3 criteria)
- =1 androgen receptor-targeted therapy (eg, abiraterone acetate/prednisone or
enzalutamide) for mCRPC with progressive disease
- =1 taxane for metastatic prostate cancer
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Chemotherapy, hormonal therapy, biologic therapy, radionuclide therapy, immunotherapy,
investigational agent, anticancer Chinese medicine, or herbal remedies = 5 half-lives
if the half-life is known, = 14 days if not known, before start of study treatment
- Continued treatment with a bisphosphonate or denosumab is allowed, if administered at
a stable dose > 28 days before start of study treatment
- Radiotherapy = 21 days (= 14 days, if single fraction of radiotherapy) before start of
study treatment
Prior treatment for prostate cancer with any of the following:
- poly ADP ribose polymerase (PARP) inhibitor
- Platinum
- Cyclophosphamide
- Mitoxantrone
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
5/02/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
2/09/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
13
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Query!
Recruitment hospital [1]
0
0
Gosford Hospital - Gosford
Query!
Recruitment hospital [2]
0
0
Liverpool Hospital - Liverpool
Query!
Recruitment hospital [3]
0
0
Calvary Mater Newcastle - Waratah
Query!
Recruitment hospital [4]
0
0
Icon Cancer Care Foundation - South Brisbane
Query!
Recruitment postcode(s) [1]
0
0
2250 - Gosford
Query!
Recruitment postcode(s) [2]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [3]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [4]
0
0
044101 - South Brisbane
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Georgia
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
New York
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Washington
Query!
Country [4]
0
0
Puerto Rico
Query!
State/province [4]
0
0
Rio Piedras
Query!
Country [5]
0
0
Spain
Query!
State/province [5]
0
0
Barcelona
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
BeiGene
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is designed to evaluate the efficacy of pamiparib in participants with metastatic
castration-resistant prostate cancer (mCRPC) positive for circulating tumor cells (CTC) with
homologous recombination deficiency (CTC-HRD). All participants will receive pamiparib. The
purpose of this study is to demonstrate that pamiparib will improve Objective Response Rate
(ORR) and Prostate-Specific Antigen (PSA) response rate
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03712930
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Study Director
Query!
Address
0
0
Guy's and St Thomas' NHS Foundation Trust
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03712930
Download to PDF